When do patients require urgent action for potential breakthrough bleeds?
Actor portrayal
Despite effective prevention of bleeding episodes with emicizumab, the risk of breakthrough bleeds persists.1 Emicizumab is not intended for the treatment of acute bleeds.2,3 Having an on-demand therapy on hand may help keep patients prepared to act quickly.
What does the data show?
Real-world data shows that breakthrough bleeds continue to happen, despite therapy with emicizumab.1,a
Actor portrayal
When would you take action?
How and when would you treat potential breakthrough bleeds? Our illustrative patient scenario will walk you through a potential situation with a patient experiencing a bleed.
aAn observational study was conducted that analyzed breakthrough bleeding patterns in patients with severe hemophilia A who were prophylactically treated with emicizumab. The study included 70 patients (42 with hemophilia A and 28 with hemophilia A with inhibitors) who completed at least 18 months of follow-up.1
See treatment guidelines
MASAC and WFH offer guidelines for the treatment of breakthrough bleeds.
References:
- Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab. J Clin Med. 2021;10(19):4303.
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.
- MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. MASAC Document #268. Accessed December 19, 2022. https://www.hemophilia.org/sites/default/files/document/files/268_Emicizumab.pdf